In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) ≥ 50% and ≥ 1%. We report KEYNOTE-010 long-term outcomes, including after 35 cycles/2 years or second-course pembrolizumab.

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Novello, Silvia;
2020-01-01

Abstract

In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) ≥ 50% and ≥ 1%. We report KEYNOTE-010 long-term outcomes, including after 35 cycles/2 years or second-course pembrolizumab.
2020
///
///
Herbst, Roy S; Garon, Edward B; Kim, Dong-Wan; Cho, Byoung Chul; Perez-Gracia, Jose L; Han, Ji-Youn; Arvis, Catherine Dubos; Majem, Margarita; Forster, Martin D; Monnet, Isabelle; Novello, Silvia; Szalai, Zsuzsanna; Gubens, Matthew A; Su, Wu-Chou; Ceresoli, Giovanni Luca; Samkari, Ayman; Jensen, Erin H; Lubiniecki, Gregory M; Baas, Paul
File in questo prodotto:
File Dimensione Formato  
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 956.94 kB
Formato Adobe PDF
956.94 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1732909
Citazioni
  • ???jsp.display-item.citation.pmc??? 106
  • Scopus 181
  • ???jsp.display-item.citation.isi??? 167
social impact